CatalystMarker
Sign in
← board

MRK

Merck Sharp & Dohme LLCdistress 3/10 · well-funded / low risk
$129.06+1%today0% from 52w high
merck.com73,000 employeesFounded 1891Rahway, NJDrug Manufacturers - General
Oncology 3
Lead: Non-small Cell Lung Cancer · est. market ~$35B (approx, global)
Revenue
$16286M
Liquidity
$6807M
Runway
—
Shares 1y
-1%

Price & events

+19.9% over 6M
$105$117$130Jan 26Apr 26Jul 2636.4Mdilution: 424B5 offering (2026-05-20)dilution: FWP offering (2026-05-19)dilution: 424B5 offering (2026-05-18)rating: JP Morgan: Overweight (2026-07-13)rating: Guggenheim: Buy (2026-07-13)rating: BMO Capital: Outperform (2026-07-13)rating: Morgan Stanley: Equal-Weight (2026-07-09)rating: RBC Capital: Outperform (2026-07-08)rating: Wells Fargo: Overweight (2026-07-08)rating: Cantor Fitzgerald: Neutral (2026-07-06)rating: B of A Securities: Buy (2026-06-30)
CatalystRating changeDilutionFinancingdashed = today
+1.2%
1D
+1.1%
1W
+7.9%
1M
+13.4%
3M
+21.0%
6M
+58.8%
1Y
+10.9%
2Y
+94.5%
5Y
+98.7%
All

Overview

Market Cap
$318.76B
Enterprise Value
$360.10B
Volume
740.03K
52 Week Range
$77.60 – $130
Total Shares
2.47B
Float Shares
2.47B
Short %
1.27%
% Held by Insiders
0.06%
% Held by Institutions
82.23%
RVOL
0.07x
Beta
0.20

Pipeline stages · 32 programs

9vHPV vaccine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-02-19
Zilovertamab vedotin, Rituximab, Cyclophosphamide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-02-26
MK-3120, EV, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-02-28
ISL, ULO, BIC/FTC/TAF
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-03-21
Raludotatug Deruxtecan, Ifinatamab Deruxtecan, Docetetaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-03-27
Calderasib, MK-3475A
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-03-28
Pembrolizumab, Standard of Care (SOC), Lenvatinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-03-30
Sacituzumab tirumotecan, Pembrolizumab, Cisplatin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-04-27
MK-2214
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-04-30
Sotatercept
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-05-24
Show all 32 programs · 22 more ▾
MK-8591A
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-05-29
Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-07-02
Gocatamig, I-DXd, Atezolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-08-31
MK-4884
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-10-04
Enlicitide Decanoate
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-11-29
coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-12-10
Belzutifan, Palbociclib, Nivolumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-12-27
Patritumab deruxtecan, Paclitaxel, Nab-paclitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-12-31
Miransertib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-02-07
MK-1045, Blinatumomab, Acetaminophen
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-07-01
MK-4716, Pembrolizumab, Cetuximab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-12-01
Molnupiravir
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2031-01-26
Docetaxel, Ifinatamab Deruxtecan, MK-5684
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2031-04-01
MK-1084, Pembrolizumab, Cetuximab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2031-08-11
Ifinatamab Deruxtecan
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2031-08-17
V181
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2031-10-24
Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2032-02-06
R-DXD, I-DXD, Docetaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2032-03-02
Vericiguat tablet, Vericiguat suspension
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2032-04-15
Nemtabrutinib, Ibrutinib, Acalabrutinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2032-06-01
Bomedemstat
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2034-12-04
Tulisokibart
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2037-12-17

Pipeline · 80 trials · 80 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2029-02-19
Estimated 50%
readout ~2029-05-05
Phase 39vHPV vaccineGenital Warts—active not recruiting
2029-02-26
Estimated 50%
readout ~2029-04-12
Phase 1/2Zilovertamab vedotin, Pembrolizumab, MK-3120Urothelial Carcinoma—recruiting
2029-02-28
Estimated 50%
readout ~2029-04-14
Phase 1/2MK-3120Bladder Cancer, Urinary Bladder Neoplasms—recruiting
2029-03-21
Estimated 50%
readout ~2029-06-04
Phase 2/3ISL, ULO, BIC/FTC/TAFHuman Immunodeficiency Virus Type 1 (HIV-1) Infection—recruiting
2029-03-27
Estimated 50%
readout ~2029-05-11
Phase 1/2Raludotatug Deruxtecan, Carboplatin, PaclitaxelOvarian Cancer Recurrent—recruiting
Show all 80 trials · 75 more ▾
ReadoutPhaseDrugIndicationEnrollStatus
2029-03-28
Estimated 50%
readout ~2029-06-11
Phase 3Calderasib, Oxaliplatin, Leucovorin/levofolinate calciumColon Adenocarcinoma, Rectal Adenocarcinoma—recruiting
2029-03-30
Estimated 50%
readout ~2029-05-14
Phase 1/2PembrolizumabMalignant Neoplasm, Carcinoma, Merkel Cell, Lymphoma—recruiting
2029-03-31
Estimated 50%
readout ~2029-05-15
Phase 1/2Zilovertamab vedotinB-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma—recruiting
2029-04-26
Estimated 50%
readout ~2029-06-10
Phase 2Zilovertamab Vedotin, Cyclophosphamide, DoxorubicinLymphoma, Large B-Cell, Diffuse (DLBCL)—active not recruiting
2029-04-27
Estimated 50%
readout ~2029-07-11
Phase 3Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonistOvarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer—recruiting
2029-04-30
Estimated 50%
readout ~2029-06-14
Phase 2MK-2214Early Alzheimer's Disease—recruiting
2029-05-17
Estimated 50%
readout ~2029-07-01
Phase 2Zilovertamab vedotin, NemtabrutinibChronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma—active not recruiting
2029-05-24
Estimated 50%
readout ~2029-07-08
Phase 2SotaterceptPulmonary Arterial Hypertension—not yet recruiting
2029-05-25
Estimated 50%
readout ~2029-08-08
Phase 39vHPV VaccinePapillomavirus Infections—active not recruiting
2029-05-29
Estimated 50%
readout ~2029-08-12
Phase 3MK-8591AHIV-1 Infection—active not recruiting
2029-07-02
Estimated 50%
readout ~2029-09-15
Phase 3Zilovertamab vedotin, Rituximab, CyclophosphamideDiffuse Large B-Cell Lymphoma—recruiting
2029-07-02
Estimated 50%
readout ~2029-08-16
Phase 2Intismeran Autogene, Pembrolizumab, CarboplatinSquamous Non-small Cell Lung Cancer—recruiting
2029-07-27
Estimated 50%
readout ~2029-10-10
Phase 3Sacituzumab tirumotecan, Vinflunine, DocetaxelBladder Cancer—recruiting
2029-08-03
Estimated 50%
readout ~2029-10-17
Phase 39vHPV vaccinePapillomavirus Infections—active not recruiting
2029-08-31
Estimated 50%
readout ~2029-10-15
Phase 1/2Gocatamig, Ifinatamab Deruxtecan (I-DXd), DurvalumabSmall Cell Lung Cancer—recruiting
2029-09-12
Estimated 50%
readout ~2029-10-27
Phase 1/2Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), CapecitabineGastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer—recruiting
2029-10-04
Estimated 50%
readout ~2029-11-03
Phase 1MK-4884Malignant Neoplasm—recruiting
2029-10-16
Estimated 50%
readout ~2029-11-30
Phase 1/2Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorinColorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer—recruiting
2029-10-23
Estimated 50%
readout ~2030-01-06
Phase 39vHPV vaccinePapillomavirus Infections—active not recruiting
2029-10-26
Estimated 50%
readout ~2030-01-09
Phase 3Intismeran autogene, PembrolizumabMelanoma—active not recruiting
2029-11-29
Estimated 50%
readout ~2030-02-12
Phase 3Enlicitide DecanoateArteriosclerosis, Hypercholesterolaemia—active not recruiting
2029-12-07
Estimated 50%
readout ~2030-02-20
Phase 3Calderasib, Pembrolizumab (, ) Berahyaluronidase alfaNon-small Cell Lung Cancer—recruiting
2029-12-10
Estimated 50%
readout ~2030-01-24
Phase 1/2coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830Small Cell Lung Carcinoma—active not recruiting
2029-12-27
Estimated 50%
readout ~2030-02-10
Phase 2BelzutifanPheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers—recruiting
2029-12-31
Estimated 50%
readout ~2030-02-14
Phase 2Patritumab deruxtecan, Pembrolizumab, PaclitaxelBreast Neoplasms, Breast Cancer—recruiting
2030-02-07
Estimated 50%
readout ~2030-03-24
Phase 2MiransertibPIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)—active not recruiting
2030-02-25
Estimated 50%
readout ~2030-03-27
Phase 1Calderasib, Pembrolizumab, carboplatinAdvanced Solid Tumors—recruiting
2030-04-18
Estimated 50%
readout ~2030-06-02
Phase 1/2Patritumab deruxtecan, Trastuzumab, Trastuzumab BiosimilarBreast Neoplasms, Breast Cancer—recruiting
2030-05-18
Estimated 50%
readout ~2030-08-01
Phase 3Sacituzumab tirumotecan, Pembrolizumab, Rescue MedicationTriple Negative Breast Neoplasms—recruiting
2030-06-25
Estimated 50%
readout ~2030-09-08
Phase 3Intismeran autogene, PembrolizumabNon-small Cell Lung Cancer—recruiting
2030-07-01
Estimated 50%
readout ~2030-08-15
Phase 1/2MK-1045Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse—recruiting
2030-11-27
Estimated 50%
readout ~2031-02-10
Phase 3Belzutifan, ZanzalintinibCarcinoma, Renal Cell—recruiting
2030-11-29
Estimated 50%
readout ~2031-01-13
Phase 1/2Gocatamig, I-DXd, AtezolizumabSmall Cell Lung Cancer Extensive Stage—recruiting
2030-12-01
Estimated 50%
readout ~2030-12-31
Phase 1MK-4716, Pembrolizumab, CetuximabMalignant Neoplasm—recruiting
2030-12-16
Estimated 50%
readout ~2031-03-01
Phase 3Pembrolizumab, Sacituzumab tirumotecan, CapecitabineTriple-Negative Breast Cancer—recruiting
2030-12-30
Estimated 50%
readout ~2031-02-13
Phase 1/2Patritumab DeruxtecanMalignant Neoplasm—recruiting
2031-01-24
Estimated 50%
readout ~2031-04-09
Phase 3Pembrolizumab (K), Paclitaxel (X), Doxorubicin (A)Breast Cancer—active not recruiting
2031-01-26
Estimated 50%
readout ~2031-04-11
Phase 3MolnupiravirCoronavirus Disease (COVID-19)—recruiting
2031-04-01
Estimated 50%
readout ~2031-05-16
Phase 1/2Docetaxel, Ifinatamab Deruxtecan, MK-5684Castration-Resistant Prostatic Cancer, Metastasis—recruiting
2031-07-08
Estimated 50%
readout ~2031-08-22
Phase 1/2MK-3120, EV, PembrolizumabBladder Cancer—recruiting
2031-08-11
Estimated 50%
readout ~2031-09-25
Phase 1/2MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecanLung Neoplasm Malignant—recruiting
2031-08-17
Estimated 50%
readout ~2031-10-01
Phase 1/2Ifinatamab DeruxtecanMalignant Neoplasm—not yet recruiting
2031-09-03
Estimated 50%
readout ~2031-10-18
Phase 2Intismeran autogene, BCGUrinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ—recruiting
2031-10-24
Estimated 50%
readout ~2032-01-07
Phase 3V181Healthy—recruiting
2031-10-26
Estimated 50%
readout ~2031-12-10
Phase 1/2Belzutifan, ZanzalintinibRenal Cell Carcinoma—recruiting
2031-10-29
Estimated 50%
readout ~2032-01-12
Phase 3Pembrolizumab, Sacituzumab Tirumotecan, BevacizumabCervical Cancer—recruiting
2032-01-04
Estimated 50%
readout ~2032-02-18
Phase 1/2Pembrolizumab, I-DXd, LeucovorinEsophageal Squamous Cell Carcinoma—recruiting
2032-02-06
Estimated 50%
readout ~2032-03-22
Phase 2Pembrolizumab (neoadjuvant), Cisplatin, GemcitabineLung Neoplasm Malignant—recruiting
2032-02-13
Estimated 50%
readout ~2032-03-29
Phase 1/2Pembrolizumab, Carboplatin, PaclitaxelCarcinoma, Non-Small-Cell Lung—recruiting
2032-02-27
Estimated 50%
readout ~2032-05-12
Phase 3Belzutifan, Zanzalintinib, CabozantinibRenal Cell Carcinoma—recruiting
2032-03-02
Estimated 50%
readout ~2032-04-16
Phase 2R-DXD, I-DXD, DocetaxelLung Neoplasm—recruiting
2032-03-12
Estimated 50%
readout ~2032-04-26
Phase 2Pembrolizumab, Carboplatin, PaclitaxelNon-small Cell Lung Cancer—recruiting
2032-03-12
Estimated 50%
readout ~2032-04-26
Phase 2Raludotatug Deruxtecan, Ifinatamab Deruxtecan, DocetetaxelCarcinoma, Non-Small-Cell Lung—recruiting
2032-04-09
Estimated 50%
readout ~2032-05-24
Phase 2Calderasib, CetuximabNeoplasm Malignant—recruiting
2032-04-15
Estimated 50%
readout ~2032-06-29
Phase 2/3Vericiguat tablet, Vericiguat suspensionHeart Failure, Left Ventricular Systolic Dysfunction—recruiting
2032-05-24
Estimated 50%
readout ~2032-08-07
Phase 3Pembrolizumab, Carboplatin, PaclitaxelEndometrial Cancer—recruiting
2032-06-01
Estimated 50%
readout ~2032-08-15
Phase 3Nemtabrutinib, Venetoclax, RituximabLeukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic, CLL, SLL—recruiting
2032-07-23
Estimated 50%
readout ~2032-10-06
Phase 2/3MK-1045, Rituximab, Rituximab biosimilarFollicular Lymphoma—recruiting
2032-09-07
Estimated 50%
readout ~2032-11-21
Phase 3Nemtabrutinib, Ibrutinib, AcalabrutinibChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma—recruiting
2032-12-15
Estimated 50%
readout ~2033-02-28
Phase 3Calderasib, DurvalumabNon-small Cell Lung Cancer—recruiting
2033-01-14
Estimated 50%
readout ~2033-02-28
Phase 2MK-1084, Pembrolizumab, CetuximabMalignant Neoplasm—recruiting
2033-02-25
Estimated 50%
readout ~2033-05-11
Phase 3Sacituzumab tirumotecan, Bevacizumab, Rescue MedicationsOvarian Neoplasms, Ovarian Cancer—recruiting
2033-03-23
Estimated 50%
readout ~2033-06-06
Phase 3Sacituzumab tirumotecan, Pembrolizumab, Rescue MedicationBreast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms—recruiting
2033-05-16
Estimated 50%
readout ~2033-07-30
Phase 3Pembrolizumab, Cisplatin, CarboplatinCarcinoma, Non-Small-Cell Lung—recruiting
2033-07-14
Estimated 50%
readout ~2033-09-27
Phase 3Patritumab deruxtecan, Paclitaxel, Nab-paclitaxelBreast Neoplasms—recruiting
2033-10-18
Estimated 50%
readout ~2034-01-01
Phase 2/3MK-1045, Blinatumomab, AcetaminophenB-cell Acute Lymphoblastic Leukemia—recruiting
2033-12-04
Estimated 50%
readout ~2034-02-17
Phase 2/3Enlicitide DecanoateHeterozygous Familial Hypercholesterolemia (HeFH)—recruiting
2034-01-14
Estimated 50%
readout ~2034-03-30
Phase 3Belzutifan, Palbociclib, NivolumabVon Hippel-Lindau Disease, Carcinoma, Renal Cell—recruiting
2034-02-21
Estimated 50%
readout ~2034-05-07
Phase 3Sacituzumab tirumotecan, Pembrolizumab, CisplatinNon Small Cell Lung Cancer—recruiting
2034-08-22
Estimated 50%
readout ~2034-11-05
Phase 3Intismeran, Pembrolizumab coformulated with berahyaluronidase alfaNon-small Cell Lung Cancer—recruiting
2034-12-04
Estimated 50%
readout ~2035-02-17
Phase 3BomedemstatThrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera—recruiting
2035-08-10
Estimated 50%
readout ~2035-09-24
Phase 2SotaterceptHypertension, Pulmonary—active not recruiting
2037-12-17
Estimated 50%
readout ~2038-03-02
Phase 3TulisokibartCrohn Disease, Colitis, Ulcerative—recruiting
2039-10-26
Estimated 50%
readout ~2040-01-09
Phase 3Calderasib, MK-3475ANon-small Cell Lung Cancer—recruiting
2043-08-04
Estimated 50%
readout ~2043-10-18
Phase 3Pembrolizumab, Standard of Care (SOC), LenvatinibSolid Tumors, Hematologic Malignancies—recruiting

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (14)

  • VIOXXROFECOXIB2004 · Discontinued
  • FOSAMAXALENDRONATE SODIUM2003 · Discontinued
  • CANCIDASCASPOFUNGIN ACETATE2001 · Discontinued
  • VIOXXROFECOXIB1999 · Discontinued
  • VIOXXROFECOXIB1999 · Discontinued
  • PEPCID RPDFAMOTIDINE1998 · Discontinued
  • TIAMATEDILTIAZEM MALATE1996 · Discontinued
  • CHIBROXINNORFLOXACIN1991 · Discontinued
  • PRIMAXINCILASTATIN SODIUM1990 · Discontinued
  • PRINZIDEHYDROCHLOROTHIAZIDE1989 · Discontinued

Capital structure — dilution & financing

Shares out: 2,469,824,415 · 9 offerings/1y · 0 PIPEs
  • 2026-05-20424B5offering
  • 2026-05-19FWPoffering
  • 2026-05-18424B5offering
  • 2025-12-03424B5offering
  • 2025-12-02FWPoffering
  • 2025-12-01424B5offering
  • 2025-09-04424B5offering
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $134 (+4% upside) · 26 analysts
  • 2026-07-13JP MorganOverweight
  • 2026-07-13GuggenheimBuy
  • 2026-07-13BMO CapitalOutperform
  • 2026-07-09Morgan StanleyEqual-Weight
  • 2026-07-08RBC CapitalOutperform
  • 2026-07-08Wells FargoOverweight

Competitors — Non-small Cell Lung Cancer

  • ABBVAbbVie Inc.$451.1B · D2
  • NVSEFNOVARTIS AG$292.0B · D3
  • PFEPFIZER INC$142.2B · D3
  • REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
  • RVMDRevolution Medicines, Inc.$40.3B · D1
  • IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
  • CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
  • MAIAMAIA Biotechnology, Inc.$78M · D5
  • AZNASTRAZENECA PLC— · D3

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.